Evaluation of in vitro efficacy of emicizumab and inhibitor bypassing coagulation complex in patient plasma. Thrombin-generation profiles on in vitro supplementation of emicizumab (Hemlibra) in (A) normal pooled plasma, (B) FVIII-depleted plasma, (C) FIX-depleted plasma, (D) plasma of the carrier II.I, (E) plasma of sibling III.I harboring p.(Gln96Arg), and (F) plasma of sibling III.II harboring p.(Gln96Arg). (G) Thrombin-generation profiles on in vitro supplementation of anti-inhibitor coagulant complex factor eight inhibitor bypassing activity in patient (III.II) plasma. Data were obtained by CAT assay with 1 pM TF for coagulation initiation. Dashed lines indicate the peak height in the control condition (pooled normal human plasma).